Mono Pharmacare (NSE:MONOPHARMA) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:MONOPHARMA Mono Pharmacare Ltd NSE:MONOPHARMA
12 GF Score
Price ₹7.85
! 6 Warning Signs
View Full Analysis

What is Mono Pharmacare Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

NSE:MONOPHARMA
12GF Score
Mono Pharmacare Ltd NSE:MONOPHARMA
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mono Pharmacare Business Description

Address 1A, Krinkal Apartment, Opposite Mahalaxmi Temple, Paldi, Ahmedabad, GJ, IND, 380007
Mono Pharmacare Ltd distributes a broad range of pharmaceutical products across India. Its portfolio includes antibiotics, antifungal medicines, cough and cold remedies, antacids, analgesics, nutraceuticals, skincare, antiseptics, cardiac and diabetic drugs, and cosmetic items. The company operates through contract manufacturing, sourcing products from various manufacturers and supplying them to healthcare providers and pharmacies. Revenue is generated through the sales and distribution of these pharmaceutical and healthcare products in the Indian market.
12GF Score

Get the complete analysis for NSE:MONOPHARMA

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹7.85
Price